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Objective: Disparities in self-reported emotional distress and subsequent pharmacologic treatment 
for emotional distress are not well understood among older adults with cancer. The main objective 
of this study is to understand racial and ethnic disparities in emotional distress medication and the 
relationship between self-reported levels of emotional distress. We hypothesize that as self-
reported levels of emotional distress increase in severity, the race and ethnic disparities in 
emotional distress medication will diminish or decrease. Our secondary aim was to understand the 
role of socioeconomic factors on racial and ethnic disparities in medication use.  
Methods: In this retrospective cohort study, we used the SEER-MHOS (2007-2012) database 
linked to Medicare Part D enrollment and claims. The main outcome was receipt of any emotional 
distress medication 90 days post-MHOS. Bivariate sample proportions and multivariate logistic 
regression were used to illustrate differences in receipt of emotional distress medication among 
key categories and race/ ethnicity. The three models of emotional distress we investigated were: 
self-reported depression in the past year, functional limitations, and emotional well-being. Results 
are reported in odds ratios and predicted margins.  
Results: A total of 8,889 beneficiaries were included in our study and 28.7% of our sample 
received medication treatment for emotional distress. There was a significant association between 
all levels of emotional distress and race/ ethnicity. Half of those reporting depression in the past 
year (50%) and nearly half of those with severe functional limitations (47%) and poor emotional 
well-being (56%) received emotional distress medication. After adjusting for all covariates, racial 
and ethnic minorities had decreased odds of receiving medication for emotional distress compared 
to non-Hispanic whites. This pattern persisted for non-Hispanic Blacks even when limiting to those 
experiencing high levels of emotional distress. Non-Hispanic Blacks reporting depression in the 
past year (AOR=0.36), severe functional limitations (AOR=0.32), and poor emotional well-being 
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(AOR=0.24) had decreased odds of receiving emotional distress medication compared to non-
Hispanic whites (p<0.001). 
Conclusion: Emotional distress may be undertreated among older adults with cancer, and 
especially for certain racial and ethnic minorities who self-report depression, functional 
limitations, and poor emotional well-being. Further research is needed to understand whether low 
levels of medication use among certain race and ethnic groups are due to utilization of other forms 


















 Race, ethnic, and socioeconomic disparities across the cancer care trajectory, from 
screening and diagnosis to treatment and survival, are well documented (Blinder & Griggs, 2013; 
Kolb et al., 2006; O’Keefe et al., 2015). Cancer is an age-related disease, with the majority of 
newly diagnosed cases occurring in adults > 65 years of age (White et al., 2014). Given the rapidly 
growing older adult population, the number of cancer survivors is projected to reach 22 million by 
2030 (Miller et al., 2019). Among older adults, primarily covered through Medicare, race and 
ethnic disparities in healthcare have been widely reported (Gornick, 2008). Social determinants of 
health, such as differences in education, income, and occupation, have been the root cause of these 
disparities translating to differences in health outcomes among racial and ethnic minorities 
(Lisovicz et al., 2008). Despite the progress and innovation in cancer care over time, the 
persistence of disparities highlights the inequities within our healthcare system. It is vital to 
continue to uncover these disparities to develop effective policies and procedures to improve 
quality of life (QoL) and overall survivorship among vulnerable populations.  
 Cancer survivors are particularly susceptible to psychological distress, which has been 
linked to poor health outcomes and known to affect demographic groups differently (Erim et al., 
2019; Kaiser et al., 2010). Cancer diagnosis and treatment cause high levels of distress for many 
patients, defined as anxiety and depressive symptoms related to the entire cancer experience 
(Berry-Stoelzle et al., 2020; Carlson & Bultz, 2003). Cancer-related distress among older adults 
can decrease quality of life (Huo et al., 2019; Weinberger et al., 2011) and impact cancer 
survivorship (Bultz & Carlson, 2006). Evidence suggests racial disparities in self-reported 
emotional distress, with Black cancer survivors reporting higher levels of emotional distress 
compared to whites (Apenteng et al., 2017). One explanation is existing socioeconomic disparities 
among racial and ethnic minorities, which may exacerbate cancer-related psychological distress 
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for survivors (Singh et al., 2017). Treatment for emotional distress among cancer survivors 
includes behavioral and pharmacologic approaches, both of which have proven to be effective (Yi 
& Syrjala, 2017). Nonetheless, studies confirm medication therapy is utilized more than behavioral 
therapy in the Medicare population (Alwhaibi et al., 2017; Findley et al., 2012). Oncologists’ 
treatment patterns for mental health distress among cancer patients also show an overwhelming 
preference for medication use, e.g. antidepressants, anti-anxiety, or sleep-aids (Granek et al., 
2018). Furthermore, medication treatment for emotional distress can be easily measured through 
health insurance administrative claims data that provide detailed records of medication utilization 
(Tyree et al., 2006). 
Though available treatments for emotional distress are effective, there continue to be 
disparities in access and quality of mental health care for racial and ethnic minorities. Alegría et 
al., 2008 found a significant difference in access to mental health treatment among racial and ethnic 
minorities compared to whites after adjustment for socioeconomic characteristics. Studies using 
SEER-Medicare have highlighted racial disparities in supportive medication treatment among 
cancer survivors, where antidepressants and anxiolytics are prescribed less frequently to Blacks, 
Hispanics, and Asians compared to non-Hispanic whites (Check et al., 2016a; Lamba et al., 2020); 
however, both of these studies limit to a specific type or stage of cancer. There is robust literature 
on racial disparities in treatment for emotional distress and, separately, levels of reported emotional 
distress. To our knowledge, no study has been conducted examining medication use by self-
reported levels of emotional distress among older adults with cancer. The relationship between 
pharmacologic therapy and patient reported emotional distress can further contribute to the 
understanding of disparities in medication treatment (Presley et al., 2020).  
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The measurement of emotional distress can vary, as some researchers use clinical diagnosis 
codes for depression (Alwhaibi et al., 2017) while others use self-reported questionnaires and 
validated distress scales (Alegría et al., 2008; Hoffman et al., 2009). Apenteng et al., 2017 utilize 
self-reported responses to the Patient Health Questionnaire (PHQ-4), a validated screening tool for 
emotional distress, to categorize levels of psychological distress. Within the SEER-MHOS dataset, 
the Veterans RAND 12-Item Health Survey (VR-12) is widely used to understand health-related 
quality of life (HRQOL) among cancer patients and survivors, including both physical component 
summary (PCS) and mental component summary (MCS) scores (Doucette et al., 2019). Alobaidi 
et al., 2019 utilize the MCS scores from the VR-12 to understand mental HRQOL on survival 
among older adults with multiple myeloma. Our focus will hone in on two of the total eight 
subscales of the VR-12 –role limitations due to emotional problems and mental health, in order to 
assess emotional distress (Kazis et al., 2019).   
Additionally, adjustment for socioeconomic factors as an analytical technique in disparities 
research has been controversial. On occasion, adjustment for socioeconomic factors, such as 
education and income, can remove significance from the race effect on a given outcome, which 
subsequently requires careful interpretation of the data (Meghani & Chittams, 2015). Racial and 
ethnic disparities are closely intertwined with socioeconomic status, both of which lead to 
differences in health outcomes (Anderson et al., 2004). The Institute of Medicine (IOM) report 
recognizes the role of socioeconomic differences in race and ethnic disparities (McGuire et al., 
2006).  
In this study, we describe the prevalence of pharmacologic therapy for emotional distress 
among older adults with cancer and aim to focus on racial and ethnic disparities. We use patient 
reported levels of emotional distress and race/ ethnicity to understand utilization of prescription 
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medication for emotional distress. We hypothesize that prescription medication utilization will 
increase with increasing levels of emotional distress severity. We test the hypothesis that racial 
and ethnic disparities in prescription medication treatment will diminish at higher self-reported 
emotional distress levels. In addition, we explore the effect of socioeconomic characteristics on 
race and ethnic disparities in pharmacologic treatment for emotional distress.   
Methods 
Data Source 
We used the Surveillance, Epidemiology and End Results (SEER)-Medicare Health 
Outcomes Survey (MHOS) data with a novel linkage to Medicare Part D claims. SEER provides 
detailed cancer registry data such as cancer type(s), stage, histology, diagnosis date, covering about 
26% of the US population (Ambs et al., 2008). The Centers for Medicare and Medicaid Services 
(CMS) administer the MHOS annually to randomly selected beneficiaries enrolled in Medicare 
Advantage (MA) plans to collect self-reported responses on sociodemographic characteristics and 
health status. MHOS is used to understand the physical and mental functioning of beneficiaries 
and has widely been used to understand HRQOL. The SEER-MHOS represents a linkage for those 
with a SEER-reported cancer who responded to the MHOS. Medicare Part D claims were linked 
for Part D-enrolled MHOS respondents for the period from 2007 to 2012. Part D claims provide 
detailed information on all oral prescription drugs covered by Medicare.  
Study Sample 
A total of 8,889 cancer patients are included in the analysis for this study (Figure 1). We 
selected beneficiaries in the SEER-MHOS dataset with a primary cancer (any invasive disease or 
Stage 0 breast cancer) diagnosis between January 2003 and December 2012. These beneficiaries 
have to complete at least one MHOS within 5 years of cancer diagnosis and between January 2008 
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and December 2012. Beneficiaries with an unknown cancer diagnosis month and diagnosis 
concurrent with autopsy were excluded. Beneficiaries who were aged >66 years at MHOS data 
and had continuous enrollment in Medicare Parts A, B, and Medicare Advantage and Part D during 
the 12 months pre-post MHOS date or until death were included. Detailed sample selection criteria 
can be found in the Presley et al., 2020, study.  
Key Outcome Measures 
The main outcome measure is receipt of prescription medications for the treatment of 
emotional distress. The categories of medications included were antidepressants, 
anxiolytics/sedatives, and antipsychotics. Relevant medications were identified based on clinical 
guidelines and the literature. Once we specified the relevant medications by generic name, we 
searched for Part D claims during the measurement period, the MHOS date and the following three 
months, including earlier fills with days supply that extended into this period. We constructed 
indicators for receipt of individual drugs, which were combined to construct indicators for any 
emotional distress medication overall and by category.  
The two key independent variables in this study were race/ ethnicity and emotional distress. 
Race/ethnicity was measured based on responses to two MHOS questions. The first, “How would 
you describe your race?” included six response categories: White, Black or African American, 
Asian, Native Hawaiian or Other Pacific Islander, American Indian or Alaskan Native, or Another 
Race (Centers for Medicare and Medicaid, 2010). Hispanic ethnicity was assessed based on 
response to: “Are you of Hispanic or Latino origin or descent?” We combined responses to the 
two questions to create four categories: non-Hispanic white, non-Hispanic Black, Hispanic, and 
Asian/ other.  
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We compared three alternative approaches to measure emotional distress based on response 
to MHOS questions: feeling depressed, functional impairment due to emotional distress, and 
emotional well-being. Self-reported depression was based on responses to the MHOS question, 
“In the past year, have you felt depressed or sad much of the time?” Responses were categorized 
into “yes” and “no”. 
Functional limitations were measured on the role-emotional subscale of the VR-12, based 
on responses to the following MHOS question, “During the past 4 weeks, have you had any of the 
following problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)?” The two problems of interest were 
“accomplished less than you would like” and “didn’t do work or other activities as carefully as 
usual.” Respondents answered the questions on a 5-point Likert scale ranging from “none of the 
time” to “all of the time.” The minimum and maximum scores were 0 and 10, respectively, after 
summing the scores for both questions. We grouped the responses into three categories as follows: 
none/ mild (score 0-4), moderate (score 5-7), and severe (score 8-10). These categorizations were 
made with a qualitative understanding of emotional distress levels; e.g. if they answered 5 for 
either question they were placed in the severe category.  
Emotional well-being was measured on the mental health subscale of the VR-12, based on 
responses to the following MHOS questions, “Have you felt calm and peaceful?” and “Have you 
felt downhearted and blue?” Respondents answered the questions on a 6-point Likert scale ranging 
from “yes, all of the time” to “no, none of the time.” A numerical score of 1 to 6 was attached to 
each level, with the highest numerical scores associated with feeling calm and peaceful none of 
the time and feeling downhearted and blue all of the time. The minimum and maximum scores 
were 0 and 12, respectively, after summing the scores for both questions. We grouped the 
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responses into three categories as follows: good/ normal (score 0-4), moderate (score 5-8), poor 
(score 9-12). 
Higher levels of emotional distress correspond to higher scores in functional limitations 
and emotional well-being. The latter two approaches to emotional distress variables were validated 
by Apenteng et al., 2017, where similar methods were employed for questions from the PHQ-4.  
 We also included beneficiary demographics such as age, sex, education, marital status, 
region (Northeast, South, Midwest, West), MA plan type (HMO or PPO/PDP), receipt of the Part 
D low-income subsidy (LIS, full or partial versus none). Although the MHOS reports family 
income, a large proportion of observations were missing responses. Instead, we included 
information on poverty rates linked at the census-tract level, based on data from the 2000 Census 
and American Community Survey.    
Statistical Analyses 
We described baseline sample characteristics overall and stratified by race/ ethnicity using 
N (proportion) for categorical variables. Chi-squared statistics were used to describe the bivariate 
unadjusted associations between study variables and race/ ethnicity, the unadjusted association 
between emotional distress and receipt of any emotional distress medication, and the unadjusted 
association between race/ ethnicity and receipt of any emotional distress medication. We used 
multivariable logistic regression analysis to test the association between receipt of prescription 
medication, and race/ethnicity and emotional distress. We estimated three parallel models, using 
the three alternative measures of emotional distress, adjusting for all other covariates. To assess 
whether the role of race/ethnicity varied by level of emotional distress, we estimated the models 
on samples stratified by emotional distress. To assess whether the estimated effect of race/ethnicity 
was influenced by controls for education, poverty and the Part D LIS, we also compared results 
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for models with and without those variables. Both odds ratios and marginal effects (e.g. predicted 
probabilities) were outputted from the logistic regression All analyses were performed using SAS 
version 9.4 and Microsoft Excel version 16.9.  
Results 
Patient Characteristics 
 Among the 8,889 beneficiaries in the sample, 67.0% were non-Hispanic white, 9.9% were 
non-Hispanic Black, 9.5% were Hispanic, and 12.9% were Asian/ Other (Table 1). The sample 
was 44% female and the majority reported being married currently (58.5%). Nearly half of the 
sample reported >10% poverty rates (48.4%), with 20.7% receiving the Part D LIS. Beneficiaries 
self-reported depression for much of the past year (15.1%), moderate-to-severe functional 
limitations (47.9%), and moderate-to-poor emotional well-being (45.8%). Sample characteristics 
varied by race/ ethnicity (p<0.001), with differences in poverty, education, Part D LIS, and self-
reported emotional distress. Over half (53.3%) of non-Hispanic Blacks and a third (32.7%) of 
Hispanics reported high poverty, compared to 11.9% of non-Hispanic whites and 15.2% of Asians. 
Non-Hispanic whites had higher educational attainment than the study sample overall and 
compared to all other race/ ethnicity categories: 52.1% of non-Hispanic whites report pursuing 
higher education compared to 23.8% of non-Hispanic Blacks, 21.0% of Hispanics, and 39.0% of 
Asians. Nearly half of non-Hispanic Black beneficiaries (26.7%) and Hispanic (41.1%) receive the 
Part D LIS, compared to a smaller percentage of Asians (32.4%) and a fraction of non-Hispanic 
whites (11.8%). Racial minorities also reported greater moderate-to-severe functional limitations 
and moderate-to-poor emotional well-being compared to non-Hispanic whites. There was no 
association between sex and race/ ethnicity.  
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Overall, emotional distress medication was received by 28.7% of our sample, with 20.1% 
receiving antidepressants, 4.3% receiving anxiolytics/ sedatives, and 1.8% receiving 
antipsychotics (Figure 2). Medication rates overall and by category (antidepressants, anxiolytics/ 
sedatives) varied by race/ ethnicity (p<0.001). Non-Hispanic whites had the highest medication 
rates (30.9%) compared to non-Hispanic Blacks (21.0%), Hispanics (28.1%), and Asians (23.5%). 
Non-Hispanic Blacks had the lowest medication rates for emotional distress overall, and for 
antidepressants and anxiolytics/ sedatives compared to all other race/ ethnicity categories.  
 Among those receiving medication for emotional distress, the majority were non-Hispanic 
white (72.9%) while a fraction of non-Hispanic Blacks, Hispanics, and Asians made up the 
remainder (Table 2). Overall, as levels of emotional distress increase, medication rates for 
emotional distress increase for all categories of race/ ethnicity.  Half of those reporting depression 
in the past year (50%) and nearly half of those with severe functional limitations (47%) and poor 
emotional well-being (56%) received emotional distress medication. Across all levels of emotional 
distress, non-Hispanic whites consistently had higher rates of medication than the overall sample. 
Over half (56%) of non-Hispanic whites who reported depression in past year received medication 
for emotional distress compared to a third (33%) of non-Hispanic Blacks. Similarly, 53% of non-
Hispanic whites reporting severe functional limitations received medication compared to 34% of 
non-Hispanic Blacks. More than half (62%) of non-Hispanic whites reporting poor emotional well-
being received medication compared to a third of non-Hispanic Blacks (33%).  
Among patients who self-reported no depression in the past year, 97.1% of the sample also 
reported none/ mild functional limitations and 97.7% reported good/ normal emotional well-being 
(Table A). Among patients who self-reported depression in the past year, 53.4% of the sample 
reported severe functional limitations and 77.5% reported poor emotional well-being. We will test 
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these three emotional distress variables independently in all subsequent logistic regression models 
due to imperfect correlations.   
Unadjusted and adjusted associations with emotional distress medication 
  We found significant associations between race/ ethnicity and receipt of prescription 
medication for emotional distress in both the unadjusted and adjusted model (Table B). In the 
adjusted model, we controlled for all covariates including levels of reported emotional distress and 
found the odds of receiving emotional distress medication were significant lower for non-Hispanic 
Blacks (AOR=0.40), Hispanics (AOR=0.64), and Asians (AOR=0.55) compared to non-Hispanic 
whites. Those receiving the Part D LIS had significantly higher odds of receiving medication for 
emotional distress (OR=1.54, AOR=1.46). Those with high educational attainment had lower odds 
of receiving medication for emotional distress although this effect was not statistically significant.  
 We found those reporting higher levels of emotional distress across the three measures of 
emotional distress had higher odds of receiving emotional distress medication in both adjusted and 
unadjusted models (Table 3). The odds of receiving emotional distress medication was 
significantly higher (p<0.001) among beneficiaries who self-report depression in the past year 
(OR=2.95, AOR=2.89) compared to those reporting no depression. Moreover, this translates into 
a predicted probability of receiving medication (0.43 versus 0.21), with an absolute difference of 
22% for those reporting depression vs no depression. The odds of receiving emotional distress 
medication was significantly higher (p<0.001) for those reporting moderate and severe functional 
limitations compared to none/ mild functional limitations in the adjusted model. Similarly, the 
odds of receiving medication for emotional distress was significantly higher (p<0.001) for those 
reporting moderate and poor emotional well-being compared to good/ normal emotional well-
being in the adjusted model. The predicted probability of those receiving emotional distress 
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medication was highest in the most severe categories of functional limitations and emotional well-
being, 0.41 and 0.48, respectively. In contrast, the predicted probability of receiving medication 
was lowest in the lowest categories of functional limitations and emotional well-being, 0.16 for 
both, with an absolutely difference of 25% and 32%, respectively.  
Adjustment for socioeconomic factors had no effect on race/ ethnicity 
 After adjusting for all covariates, including those closely tied to socioeconomic status such 
as education, poverty, and Part D LIS, all racial and ethnic minorities had significantly lower odds 
of receiving medication for emotional distress (p<0.001) (Table 4). This translates into a predicted 
probability of 0.42 for non-Hispanic whites versus 0.22 for non-Hispanic Blacks. After removing 
education, poverty, and Part D LIS from the model, racial and ethnic minorities continued to have 
a significantly lower odds of receiving medication for emotional distress (p<0.001), though the 
odds were slightly biased towards the null. This translates into a predicted probability of 0.40 for 
non-Hispanic whites versus 0.23 for non-Hispanic Blacks. 
Stratifying by levels of emotional distress 
 Models were stratified by levels of emotional distress and reported both adjusted odds 
ratios and predicted probabilities to understand whether the race/ ethnicity disparities in 
medication for emotional distress diminishes with higher reported levels of emotional distress 
(Table 5). The probability of receiving emotional distress medication was higher for all categories 
of race/ ethnicity for those reporting depression in the past year compared to those reporting no 
depression. After stratifying by levels of depression (depression = yes), non-Hispanic Blacks had 
significantly lower odds of receiving emotional distress medication (AOR=0.36) compared to non-
Hispanic whites (p<0.001). Similarly, the predicted probability of receiving emotional distress 
medication increased with increasing levels of severity in both functional limitations and 
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emotional well-being across all categories of race/ ethnicity. Interestingly, non-Hispanic Blacks 
reporting poor emotional well-being had significantly lower odds of receiving medication for 
emotional distress (AOR=0.24) compared to non-Hispanic whites (p<0.001). The odds of 
receiving emotional distress medication for Hispanics and Asians were not significantly different 
compared to non-Hispanic whites among those reporting poor emotional well-being. 
Correspondingly, non-Hispanic Blacks who report severe functional limitations had lower odds of 
receiving emotional distress medication (AOR=0.32) compared to non-Hispanic whites (p<0.001). 
In other words, non-Hispanic Blacks reporting severe functional limitations were half as likely 
(0.29 vs. 0.57) to receive medication for emotional distress compared to that of non-Hispanic 
whites, with an absolute difference of 28%. In the most severe categories of emotional distress, 
there was no significant difference in the odds of receiving medication for Hispanics compared to 
non-Hispanic whites. Asians had significantly (p<0.001) lower odds of receiving medication for 
emotional distress in all levels of emotional distress aside from poor emotional well-being, which 
was not statistically significant from non-Hispanic whites.  
Discussion 
 In this large, U.S. population-based study, we found race and ethnic disparities in receipt 
of pharmacologic therapy for emotional distress, even when controlling for level of emotional 
distress. Using SEER-MHOS data with a novel linkage to Part D Medicare claims, we found a 
significant association between receipt of emotional distress medication and levels of emotional 
distress. As reported emotional distress increases in severity, beneficiaries had higher odds and 
probability of receiving medication, which was expected. Disparities persisted, particularly for 
non-Hispanic Black cancer survivors, even conditioning on reported levels of emotional distress. 
The disparities in treatment diminished with higher levels of emotional distress for Hispanic cancer 
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survivors and little change among Asian cancer survivors. These findings emphasize the 
importance of developing policies and procedures to eliminate these disparities and ensure all 
cancer survivors are receiving adequate treatment for emotional distress.  
 Our results provide further evidence of racial and ethnic disparities in pharmacologic 
therapy among patients who self-report emotional distress. After adjusting for all covariates, racial 
and ethnic minorities had decreased odds of receiving medication for emotional distress compared 
to non-Hispanic whites. Non-Hispanic Black patients, despite reporting depression, severe 
functional limitations, or poor emotional well-being, were less likely to receive medication for 
emotional distress compared to non-Hispanic whites. In our study, approximately 28.7% of older 
adults with cancer received any emotional distress medication, and these findings are consistent 
with the literature in documenting patterns of psychotropic medications among older adult cancer 
survivors (Hawkins et al., 2017). Our findings are consistent with several studies noting racial 
differences in antidepressant treatment among patients with and without cancer (Check et al., 
2016b; Findley et al., 2012; Han & Liu, 2005; McGregor et al., 2020). Interestingly, the disparities 
in treatment for emotional distress diminished at high levels of emotional distress for Hispanics 
compared to non-Hispanic whites. We found that adjustment for socioeconomic characteristics 
had little effect on the race and ethnic disparity in emotional distress medication treatment.  
There are many explanations for the cause of these disparities, many of which are rooted 
in systemic factors such as historic socioeconomic differences between racial and ethnic minority 
groups compared to the white population or systemic racism transcending through the health care 
system (Gollust et al., 2018). These factors create inequities in access to care, namely mental health 
care services, which historically have been underutilized by minority populations (Aklin & 
Gómez, 2017). Furthermore, minority populations may not seek care due to language barriers, 
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stigma, or cultural preferences (Jimenez et al., 2012; Rao et al., 2007). It is increasingly vital to 
highlight disparities across the continuum of mental health care to find solutions for groups most 
at risk.  
Fiscella & Williams (2004) explain the complex relationship between socioeconomic 
factors, race, and health as a cause of health disparities, namely the effect of institutional racism –
including factors such as education, income, and wealth. Older adults of low socioeconomic status 
are particularly vulnerable as they experience greater functional limitations and decline (Fiscella 
& Williams, 2004). Our results, after controlling for a few socioeconomic factors, continued to 
demonstrate significance of the race/ethnicity effect. Other studies have found race and ethnic 
disparities to persist despite controlling for socioeconomic factors (Du et al., 2007). These findings 
show that there may be barriers to emotional distress treatment not directly rooted in the following 
socioeconomic factors: education, poverty, and Part D LIS.  
Conversely, our findings also show that those with the Part LIS had higher odds of 
receiving medication for emotional distress, which is evidence for an affordability issue. The LIS 
allows for reduced Part D premiums and cost-sharing to increase access to prescription 
medications and varies by income level (Stuart et al., 2012). We suggest that there may be 
beneficiaries in this study who do not qualify for the LIS and still face financial hardship in 
prescription drug coverage, especially those of lower socioeconomic status.  
The results of our study highlight undertreatment of emotional distress among a nationally 
representative sample of older adults with cancer. Beneficiaries, especially racial and ethnic 
minorities, who report levels of emotional distress receive inadequate pharmacologic treatment for 
emotional distress. These findings highlight the need for more substantial mental health treatment 




 It is worth noting a few limitations of this study, which are typically associated with the 
use of survey data and administrative claims. SEER-MHOS data is limited to beneficiaries enrolled 
in Medicare Advantage (MA) plans and may experience differences in symptom report and 
treatment compared to those in traditional Medicare plans.  
Our main outcome of interest was pharmacologic therapy for emotional distress through 
Part D Medicare claims, but it is widely known that other forms of treatment (psychotherapy, 
cognitive-behavioral, social support, community networks) are utilized to alleviate emotional 
distress. Furthermore, certain racial and ethnic minorities may rely on non-medication forms of 
therapy that were not measured in this study. This may show an exaggerated effect between certain 
racial and ethnic groups and receipt of prescription medication for emotional distress.   
Despite these limitations, our study has strengths including a large population-based sample of 
older adults with cancer and the linkage between SEER-MHOS and Part D claims. We were able 
to capture self-reported emotional distress and subsequent pharmacologic therapy for the treatment 
of emotional distress. To our knowledge, such a study documenting the relationship between self-
reported 
Conclusion 
 In conclusion, racial and ethnic minorities were less likely to receive prescription 
medication for emotional distress compared to non-Hispanic whites, overall and when stratifying 
by levels of emotional distress. These disparities are partly due to systemic issues such as 
socioeconomic inequities as well as personal and cultural attitudes towards mental health 
treatment. Innovative approaches to mental health treatment and solutions to mitigate the effect of 
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institutionalized racism on health will be necessary to eliminate race and ethnic disparities in 
treatment for emotional distress among older adults with cancer. 
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Table 1. Description of study sample overall and by race ethnicity (N=8,889)      














  % 8889 % % % % 
Self-reported depression in the past year       <.0001 
    No 84.9 7547 87.9 78.3 75.2 81.6  
    Yes 15.1 1342 12.1 21.7 24.9 18.4  
Functional limitations       <.0001 
    None/ Mild  52.1 4628 55.8 45.6 41.4 45.3  
    Moderate 35.2 3132 33.4 38.9 40.7 38.3  
    Severe 12.7 1129 10.9 15.5 17.9 16.4  
Emotional well-being       <.0001 
    Good/ Normal 54.3 4824 58.2 43.8 45.6 48.4  
    Moderate 40.6 3607 37.4 50.1 45.3 46.3  
    Poor 5.2 458 4.4 6.1 9.1 5.3  
Age group       <.0001 
    66-69 25.6 2279 24.5 34.5 28.9 22.5  
    70-74 28.1 2498 27.7 29.4 31.1 27.1  
    75-79 22.5 2004 23.4 18.8 20.8 22.5  
    80+ 23.7 2108 24.5 17.3 19.1 28.0  
Sex, n       0.15 
    Male 55.6 4942 55.5 53.4 58.8 55.4  
    Female 44.4 3947 44.5 46.6 41.2 44.6  
Education       <.0001 
    < High school diploma 24.6 2187 15.9 44.6 55.5 32.2  
     High school graduate 30.8 2734 32.0 31.7 23.6 28.8  
     > High school diploma 44.6 3968 52.1 23.8 21.0 39.0  
Marital status       <.0001 
     Currently married 58.5 5203 61.1 37.7 58.9 60.7  
     Formerly married 37.5 3335 35.6 54.0 36.7 35.6  
     Never married 4.0 351 3.3 8.4 4.4 3.7  
Poverty rates       <.0001 
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     Low (0 to <5%) 25.0 2219 29.6 6.2 12.2 24.4  
     5 to < 10% 26.6 2367 29.5 11.7 18.7 29.0  
     10 to < 20% 30.0 2666 29.0 28.5 36.5 31.4  
     High (20 to 100%) 18.4 1637 11.9 53.6 32.7 15.2  
Part D LIS       <.0001 
    Yes  20.7 1838 11.8 46.7 41.1 32.4  
    No 79.3 7051 88.3 53.3 58.9 67.6  
Plan type◦       0.0002 
    HMO 92.2 8191 92.1 93.4 94.7 89.6  
    PPO/ PDP 7.9 698 7.9 6.6 5.3 10.4  
Region       <.0001 
    Northeast 13.8 1228 14.4 21.6 12.3 6.0  
    South 9.4 838 12.0 8.4 2.1 2.3  
    Midwest-Central 23.0 2047 23.2 54.6 5.6 10.7  
    West 53.7 4776 50.5 15.4 80.0 81.0  
MHOS Survey year       <.0001 
2008 19.5 1730 20.1 15.8 16.8 20.8  
2009 25.7 2288 26.3 21.6 23.8 27.3  
2010 20.7 1839 19.9 23.8 24.0 19.9  
2011 18.5 1641 18.3 21.2 19.3 16.7  
2012 15.7 1391 15.3 17.7 16.1 15.4   
*p-value for χ2 test (categorical variable)    
   
 
◦ Plan type includes health maintenance organization (HMO), preferred provider organizations (PPO), and prescription drug plans (PDP)   
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Hispanic Asian, Other 
Overall, % p* 
% % % % 
72.9 7.3 9.3 10.6 
Self-reported depression 
in the past year 
     
 <.0001 
    No 27% 18% 20% 19% 25% ▴ 
    Yes 56% 33% 51% 42% 50% ▴ 
Functional limitations      
 <.0001 
    None/ Mild  22% 15% 17% 15% 20% ▴ 
    Moderate 38% 23% 32% 27% 34% ▴ 
    Severe 53% 34% 46% 37% 47% ▴ 
Emotional well-being       <.0001 
    Good/ Normal 22% 11% 18% 14% 20% ▴ 
    Moderate 41% 28% 32% 31% 37% ▴ 
    Poor 62% 33% 57% 48% 56%   
*p-value for χ2 test (categorical variable)        








Table 3. Bivariate and multivariate associations and predicted probabilities between emotional distress and medication for emotional distress    
 Crude Adjusted* Margins 





Self-reported depression in the 
past year 
            
    No 1.00 - - 1.00 - - 0.21 0.01 0.19 0.23 
    Yes 2.95 (2.62, 3.33) <.0001 2.89 (2.55, 3.28) <.0001 0.43 0.02 0.39 0.47 
Functional limitations             
    None/ Mild  1.00 - - 1.00 - - 0.16 0.01 0.14 0.18 
    Moderate 2.01 (1.81, 2.22) 0.16 2.07 (1.86, 2.30) <.0001 0.29 0.01 0.26 0.32 
    Severe 3.48 (3.04, 4.00) <.0001 3.58 (3.09, 4.15) <.0001 0.41 0.02 0.37 0.45 
Emotional well-being             
    Good/ Normal 1.00 - - 1.00 - - 0.16 0.01 0.14 0.18 
    Moderate 2.35 (2.13, 2.59) 0.55 2.37 (2.14, 2.63) <.0001 0.31 0.02 0.28 0.34 
    Poor 5.14 (4.22, 6.26) <.0001 4.87 (3.96, 5.99) <.0001 0.48 0.03 0.43 0.54 
▵ p-value for χ2 test (categorical variable) 
         
* Adjusted for all covariates 
          
Table 4. Multivariable logistic regression with and without adjustment for socioeconomic factors      
 
Adjusted Margins Excluding Part D LIS, Poverty, Education Margins 




OR** (95% CI) p▵ Mean 
Standard 
Error 
Race ethnicity      
   
     
  
    Non-Hispanic White 1.00 - - 0.42 0.02 1.00 - - 0.40 0.02 
    Non-Hispanic Black 0.40 (0.33, 0.49) <.0001 0.22 0.02 0.46 (0.38, 0.55) <.0001 0.23 0.02 
    Hispanic 0.64 (0.53, 0.76) <.0001 0.32 0.02 0.746 (0.63, 0.89) 0.0008 0.33 0.02 
    Asian, Other  0.55 (0.47, 0.65) <.0001 0.29 0.02 0.617 (0.53, 0.72) <.0001 0.29 0.02 
▵ p-value for χ2 test (categorical variable) 
        
* Adjusted for all covariates 
         
** Adjusted model excluding Part D LIS, education, and poverty rates 
      
 27 
 
Table 5. Multivariable logistic regression and predicted probabilities for the association between race ethnicity and emotional distress medication stratified levels of emotional distress 
Depression Depression = No Depression = Yes      
Characteristic Adjusted OR* 
(95% 






CI) p▵ Mean 
Standard 
Error 
     
     
Race ethnicity     
   
           
    Non-Hispanic White 1.00 - - 0.30 0.02 1.00 - - 0.55 0.03 
     
    Non-Hispanic Black 0.424 (0.34, 0.53) <.0001 0.16 0.02 0.361 
(0.25, 
0.53) <.0001 0.31 0.04 
     
    Hispanic 0.552 (0.44, 0.69) <.0001 0.19 0.02 0.937 
(0.65, 
1.34) 0.724 0.54 0.05 
     
    Asian, Other  0.546 (0.45, 0.66) <.0001 0.19 0.02 0.587 
(0.42, 
0.83) 0.002 0.42 0.05 
     
Emotional Well-Being Good/ Normal Moderate Poor 
Characteristic Adjusted OR* 
(95% 












CI) p▵ Mean 
Standard 
Error 
Race ethnicity                               
    Non-Hispanic White 1.00 - - 0.22 0.02 1.00 - - 0.43 0.02 1.00 - - 0.70 0.06 
    Non-Hispanic Black 0.38 (0.27, 0.54) <.0001 0.10 0.02 0.437 
(0.34, 
0.57) <.0001 0.25 0.03 0.242 
(0.12, 
0.51) 2E-04 0.36 0.09 
    Hispanic 0.668 (0.50, 0.90) 0.008 0.16 0.02 0.611 
(0.47, 
0.79) 2E-04 0.31 0.03 1.114 
(0.61, 
2.05) 0.727 0.72 0.08 
    Asian, Other  0.494 (0.38, 0.65) <.0001 0.12 0.02 0.604 
(0.49, 
0.75) <.0001 0.31 0.03 0.557 
(0.30, 
1.04) 0.066 0.56 0.09 
Functional Limitations None/ Mild Moderate Severe 
Characteristic Adjusted OR* 
(95% 












CI) p▵ Mean 
Standard 
Error 
Race ethnicity                               
    Non-Hispanic White 1.00 - - 0.25 0.02 1.00 - - 0.38 0.02 1.00 - - 0.57 0.04 
    Non-Hispanic Black 0.525 (0.38, 0.72) <.0001 0.15 0.02 0.363 
(0.27, 
0.49) <.0001 0.18 0.02 0.32 
(0.20, 
0.51) <.0001 0.29 0.05 
    Hispanic 0.599 (0.44, 0.82) 0.002 0.16 0.02 0.626 
(0.47, 
0.83) 0.001 0.27 0.03 0.709 
(0.47, 
1.06) 0.096 0.48 0.06 
    Asian, Other  0.553 (0.42, 0.72) <.0001 0.15 0.02 0.547 
(0.43, 
0.70) <.0001 0.25 0.03 0.522 
(0.36, 
0.75) 5E-04 0.40 0.05 
▵ p-value for χ2 test (categorical variable)              
* Adjusted for all covariates  
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Appendix 
Table A. Correlations between emotional distress variables    
 Functional Limitations 
Depression 
None/ Mild Moderate Severe Marginal 
% % % % 
No 97.1 80.7 46.6 84.9 
Yes 2.9 19.4 53.4 15.1 
Marginal (%) 52.1 35.2 12.7  
     
 Emotional Well-Being 
Depression 
Good/ Normal Moderate Poor Marginal 
% % % % 
No 97.7 75.8 22.5 84.9 
Yes 1.3 24.2 77.5 15.1 
Marginal (%) 54.3 40.6 5.2  
     
 Functional Limitations 
Emotional Well-Being 
None/ Mild Moderate Severe Marginal 
% % % % 
Good/Normal 74.6 23 2.5 54.3 
Moderate 27.9 52 20.1 40.6 
Poor 5.5 32.5 62 5.2 





Table B. Unadjusted and adjusted associations between study variables and receipt of prescription medication for emotional distress (N=2,549)* 
Characteristic Unadjusted OR  95% CI p▵ Adjusted OR** (95% CI) p▵ 
Race ethnicity      
  
    Non-Hispanic White 1.00 - - 1.00 - - 
    Non-Hispanic Black 0.60 (0.50, 0.71) 0.0001 0.40 (0.33, 0.49) <.0001 
    Hispanic 0.87 (0.74, 1.02) 0.06 0.64 (0.53, 0.76) <.0001 
    Asian, Other  0.69 (0.59, 0.80) 0.05 0.55 (0.47, 0.65) <.0001 
Self-reported depression in the past year   
 
    
    No 1.00 - - 1.00 - - 
    Yes 2.95 (2.62, 3.33) <.0001 2.89 (2.55, 3.28) <.0001 
Functional limitations      
  
    None/ Mild  1.00 - - 1.00 - - 
    Moderate 2.01 (1.81, 2.22) 0.16 2.07 (1.86, 2.30) <.0001 
    Severe 3.48 (3.04, 4.00) <.0001 3.58 (3.09, 4.15) <.0001 
Emotional well-being        
    Good/ Normal 1.00 - - 1.00 - - 
    Moderate 2.35 (2.13, 2.59) 0.55 2.37 (2.14, 2.63) <.0001 
    Poor 5.14 (4.22, 6.26) <.0001 4.87 (3.96, 5.99) <.0001 
Age group        
    66-69 1.00 - - 1.00 - - 
    70-74 0.79 (0.70, 0.90) 0.02 0.75 (0.66, 0.86) <.0001 
    75-79 0.83 (0.72, 0.94) 0.26 0.74 (0.64, 0.85) <.0001 
    80+ 0.86 (0.76, 0.98) 0.87 0.65 (0.57, 0.75) <.0001 
Sex, n      
 
 
    Male 1.00 - - 1.00 - - 
    Female 1.87 (1.70, 2.05) <.0001 1.76 (1.59, 1.95) <.0001 
Education        
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    < High school diploma 1.00 - - 1.00 - - 
     High school graduate 0.88 (0.78, 1.00) 0.84 0.87 (0.76, 1.00) 0.0491 
     > High school diploma 0.79 (0.71, 0.89) 0.0004 0.87 (0.76, 0.99) 0.0377 
Marital status        
     Currently married 1.00 - - 1.00 - - 
     Formerly married 1.39 (1.27, 1.53) 0.0001 1.08 (0.97, 1.20) 0.1801 
     Never married 1.17 (0.92, 1.48) 0.74 0.95 (0.74, 1.23) 0.7009 
Poverty rates        
     Low (0 to <5%) 1.00 - - 1.00 - - 
     5 to < 10% 1.27 (1.12, 1.45) 0.038 1.19 {1.04, 1.37) 0.0119 
     10 to < 20% 1.26 (1.11, 1.42) 0.063 1.10 (0.96, 1.26) 0.1858 
     High (20 to 100%) 1.17 (1.02, 1.35) 0.96 1.02 (0.87, 1.21) 0.8029 
Part D LIS        
    No 1.00 - - 1.00 - - 
    Yes  1.54 (1.38, 1.71) <.0001 1.37 (1.20, 1.56) <.0001 
Plan type        
    HMO 1.00 - - 1.00 - - 
    PPO/ PDP 1.01 (0.85, 1.19) 0.94 0.91 (0.76, 1.09) 0.3213 
Region        
    Northeast 1.00 - - 1.00 - - 
    South 1.30 (1.07, 1.59) 0.38 1.27 (1.03, 1.57) 0.0253 
    Midwest-Central 1.42 (1.21, 1.66) 0.002 1.40 (1.18, 1.67) 0.0001 
    West 1.26 (1.09, 1.46) 0.59 1.26 (1.08, 1.47) 0.0042 
MHOS year        
2008 1.00 - - 1.00 - - 
2009 1.11 (0.96, 1.27) 0.75 1.17 (1.01, 1.36) 0.033 
2010 1.09 (0.94, 1.27) 0.56 1.07 (0.91, 1.24) 0.4202 
2011 1.18 (1.01, 1.37) 0.33 1.18 (1.00, 1.38) 0.0439 
2012 1.25 (1.07, 1.46) 0.03 1.25 (1.06, 1.47) 0.0076 
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* Adjusted models report OR for functional limitations model and AORs did not vary drastically between models.  
▵ p-value for χ2 test (categorical variable)      
** Adjusted for all covariates  
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